DNA X, Inc. 8-K

What Happened
DNA X, Inc. (formerly Sonim Technologies) filed an 8-K reporting that CEO and director Peter Liu resigned effective January 30, 2026, and Chief Commercial Officer Charles Becher resigned effective January 29, 2026. The company and each executive entered into separation and release agreements that include general releases of claims. Following Liu’s departure, the board appointed Scott Walker as a director on January 30, 2026.

Key Details

• CEO resignation: Peter Liu resigned effective January 30, 2026. His separation agreement requires a general release and modifies severance timing.
  • Severance for Liu: $855,000 total; payable in two tranches — first payment three days after he signs the separation agreement, second payment on March 15, 2026. (Previously would have been a single lump sum within 30 days of separation.)
• CCO resignation: Charles Becher resigned effective January 29, 2026 (notice given February 3, 2026). His separation agreement includes a general release.
  • Severance for Becher: $250,000 total; payable in one lump sum within 30 days of January 29, 2026. (Previously would have been equal monthly installments over 12 months.)
• Director appointment: Scott Walker was appointed to the board on January 30, 2026. He is a co‑founder and executive chairman/CEO of DNA Holdings and may have an indirect material interest in prior agreements between DNA X and DNA Holdings. The appointment was made under DNA Holdings’ director-designation right pursuant to a December 15, 2025 Membership Interest Purchase Agreement; related financings include a $1.2M convertible promissory note bearing 10% interest.

Why It Matters
These are material leadership changes: the company lost its CEO and chief commercial officer, and a director designated by a recent investor (DNA Holdings) joined the board. The separation agreements create near-term cash obligations totaling $1,105,000 (combined severance) with specified payment dates, which are concrete cash outflows investors can expect in the coming weeks/months. The new director’s connection to DNA Holdings and the previously disclosed financing arrangements may affect board oversight and governance; the filing notes his ownership interest and that the DNA Agreements were negotiated at arm’s length.